Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease

Table 1 Effects of RGZ on blood biochemistry and hepatic parameters (mean ± SE)

Parameters	Control (n = 6)	NAFLD (n = 11)	RGZ-treated NAFLD (n = 11)
Glucose (mmol/L)	6.48 ± 0.32	7.31 ± 0.20a	6.26 ± 0.16c
Insulin (mU/L)	20.41 ± 1.85	27.03 ± 1.48a	21.07 ± 1.19c
HOMA-IR	5.90 ± 0.58	8.93 ± 0.48a	5.95 ± 0.41c
Leptin (μg/L)	2.63 ± 0.13	4.21 ± 0.09a	3.75 ± 0.05ac
Adiponectin (mg/L)	2.22 ± 0.05	1.64 ± 0.07a	1.91 ± 0.10ac
Free fatty acid (μmol/L)	361.0 ± 42.6	539.1 ± 32.1a	401.0 ± 32.9c
Triglycerides (mmol/L)	0.51 ± 0.04	1.21 ± 0.04a	0.82 ± 0.06ac
Cholesterol (mmol/L)	1.45 ± 0.14	2.69 ± 0.11a	2.38 ± 0.11a
Body weight (g)	563.2 ± 9.6	581.6 ± 9.7	571.4 ± 9.1
Liver weight (g)	13.90 ± 0.53	26.51 ± 1.96a	15.86 ± 1.06ac
Liver weight index (%)	2.48 ± 0.05	4.51 ± 0.17a	3.00 ± 0.16c
Alanine aminotransferase (U/L)	57.2 ± 5.8	100.9 ± 7.2a	53.6 ± 5.8c
Aspartate aminotransferase (U/L)	164.4 ± 11.8	197.5 ± 9.1a	151.2 ± 9.5c
Alkaline phosphatase (U/L)	84.8 ± 6.1	174.6 ± 11.6a	87.3 ± 4.9c

^aP < 0.05 vs control group,

^cP < 0.05 vs NAFLD group. HOMA-IR: Homeo-stasis model assessment-insulin resistance index.